

First patient treated with proton therapy in Toyohashi, Japan

First treatment conducted with the IBA Proteus®ONE compact proton therapy solution in Japan

Louvain-la-Neuve, Belgium, 03 October 2018 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce that the medical team from the Narita Memorial Proton Center in Toyohashi, Japan, has treated the first patient with the IBA Proteus[®]ONE compact proton therapy solution. On 7 September, the patient was treated for prostate cancer with proton therapy in order to preserve the surrounding healthy tissue. He is the first patient in Japan being treated with proton therapy equipment made by a foreign manufacturer.

The treatment is being delivered using the single room Proteus®ONE solution at the Narita Memorial Proton Center, which was installed within 11 months by IBA. Proteus®ONE is the only truly compact Image Guided Intensity Modulated Proton Therapy (IG-IMPT) solution in the industry. It has a unique open gantry environment designed to ease the work of radiation therapists during the treatment workflow and optimize the patient experience by providing a comfortable and calming environment. This compact design enables easy installation, operation and financing.

Olivier Legrain, Chief Executive Officer at IBA, commented: "We are delighted that the first treatment has been delivered successfully in Toyohashi. This is an important milestone for IBA as it is the first time proton therapy equipment made by a foreign manufacturer has been used in Japan to treat a patient. This reinforces IBA's position as the world's fastest proton therapy provider, from contract signature to the treatment of patients."

Makoto Narita MD, Chairman, Narita Memorial Hospital in Toyohashi added: "The delivery of the first proton therapy treatment is a great achievement for the development of cancer care in our community. We are pleased to collaborate with IBA, the global leader in proton therapy, as they have the expertise to deliver and support a fully functional compact proton therapy center in such a short time. We are excited by the prospect of continuing to provide advanced radiation treatment to cancer patients in our community whilst minimizing the side effects of the radiation therapy."

Ends

Press release | 03/10/2018

IBA | Ion Beam Applications SA Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Nivelles | VAT : 0428.750.985 T +32 10 47 58 11 | F +32 10 47 58 10 | info@iba-group.com | iba-worldwide.com





About Proteus®ONE

Proteus[®]ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus[®]ONE is smaller, more affordable, and easier to install and operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus[®]ONE allows you to think big but scale smart.

*Proteus®ONE is the brand name of a configuration of the Proteus®235.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: <u>www.iba-worldwide.com</u>

About Narita Memorial Proton Center (Toyohashi)

Narita Memorial Proton Center was launched by the Meiyokai Social Medical Corporation in April 2018 as a dedicated proton therapy facility.

The Meiyokai Social Medical Corporation was founded in Toyohashi City, Aichi in 1951. Its mission consists of "Aiming for advanced medical treatments based on kindness and warmth towards people". Through this mission, it provides medical treatments which meet the needs of its patients. By fully utilizing the flexibility of its private hospital, it continues to contribute to the development of advanced medical care in the region.

For further information, please contact: IBA

Daniel Ernult Proton Therapy Marketing Associate Tel +32 10 201 287 communication@iba-group.com

Press release | 03/10/2018

